Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Ibrutinib Suspension and Sprinkle Formulations
NCT02390609Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ibrutinib in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and Waldenström's macroglobulinemia (WM) (10 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration, Time to Reach Maximum Plasma Concentration and 5 more. Started Mar 2015; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)Waldenström's macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT02390609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02390609.